CD274 and non-small cell lung carcinoma: In four patients experiencing a recurrence of NSCLC after anti-PD-L1 treatment, Gong et al. identified two types of stably expressed sPD-L1 (PD-L1v242 and PD-L1v229), which act as negative regulators in anti-PD-L1 antibody treatment by competing with membrane-type PD-L1 (93).